MedTrace Logo

Consistency Between Treatment Responses in PDO Models and Clinical Outcomes in Gastric Cancer

NCT05203549 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 250

Last updated 2022-01-24

No results posted yet for this study

Summary

Gastric cancer is the fourth leading cause of cancer-related death worldwide. Accurate assessment of the clinical responses to current treatment regimens is key to improving the prognosis and prolonging the survival of patients. In this study, two hundred and fifty patients with gastric cancer who ought to receive neoadjuvant therapy, conversion therapy or palliative chemotherapy will be enrolled, and patient-derived organoids from their tumor biopsies will be used to test the sensitivity of chemotherapy drugs which mainly include 5-fluorouracil, irinotecan, oxaliplatin and paclitaxel.

Conditions

Interventions

PROCEDURE

Tumor biopsy

Patients with gastric cancer will undergo tumor biopsy before receiving neoadjuvant therapy, conversion therapy, or palliative therapy

Sponsors & Collaborators

  • Shanghai Zhongshan Hospital

    collaborator OTHER

  • D1 Medical Technology (Shanghai) Co., Ltd, China

    lead INDUSTRY

Principal Investigators

  • Xuefei Wang, MD · Shanghai Zhongshan Hospital

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-05-01
Primary Completion
2023-01-31
Completion
2023-06-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05203549 on ClinicalTrials.gov